Loading
Liverpool molecular scientist behind the EUROPAC registry's laboratory work and the biomarker analyses of the ESPAC trial samples.
Bill Greenhalf is a Reader in Molecular and Clinical Cancer Medicine at the University of Liverpool (Institute of Systems, Molecular and Integrative Biology). He works on the molecular side of the EUROPAC registry of familial pancreatic cancer and hereditary pancreatitis and on biomarker studies from the ESPAC trials, including the ESPAC-3 analysis of tumour hENT1 expression and survival from gemcitabine (Journal of the National Cancer Institute 2014) and the Liverpool Experimental Cancer Medicine Centre biomarker discovery programme (ISRCTN74588872).
| Title | Journal | Year |
|---|---|---|
| Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial | Journal of the National Cancer Institute | 2014 |
| European Registry of Hereditary Pancreatic Diseases (EUROPAC): protocol for primary and secondary screening in individuals at high risk of pancreatic cancer | BMJ Open | 2025 |
Shares Chris Halloran, ESPAC-3, Liverpool University Hospitals HPB centre (Aintree), Pancreatic ductal adenocarcinoma and the tags pancreatic, uk.
Shares EUROPAC, Pancreatic ductal adenocarcinoma and the tags pancreatic, uk.
Shares Liverpool University Hospitals HPB centre (Aintree), Pancreatic ductal adenocarcinoma and the tags pancreatic, uk.
Shares Pancreatic ductal adenocarcinoma and the tags pancreatic, uk.
Shares EUROPAC, Pancreatic ductal adenocarcinoma and the tag uk.
Shares EUROPAC, Pancreatic ductal adenocarcinoma and the tag uk.
Shares Pancreatic ductal adenocarcinoma and the tags pancreatic, uk.
Shares Pancreatic ductal adenocarcinoma and the tags pancreatic, uk.